Vanda Pharmaceuticals Inc. (VNDA) › Weighted Average Diluted SharesVanda Pharmaceuticals Inc. (VNDA) — Weighted Average Diluted SharesAnnual figures by period end, from SEC filings.2009-12-31: 27.02M2010-12-31: 28.53M2011-12-31: 28.11M2012-12-31: 28.23M2013-12-31: 30.35M2014-12-31: 36.69M2015-12-31: 42.25M2016-12-31: 43.45M2017-12-31: 44.74M2018-12-31: 53.05M2019-12-31: 54.85M2020-12-31: 55.19M2021-12-31: 56.92M2022-12-31: 56.98M2023-12-31: 57.56M2024-12-31: 58.15M2025-12-31: 58.93M58.93M2009-12-31Weighted Average Diluted Shares (shares)2025-12-31Period endedWeighted Average Diluted SharesChange YoYSource filing2025-12-3158.93M+1.3%2026-02-12From 2025-01-012024-12-3158.15M+1.0%2026-02-12From 2024-01-012023-12-3157.56M+1.0%2026-02-12From 2023-01-012022-12-3156.98M+0.1%2025-02-14From 2022-01-012021-12-3156.92M+3.1%2024-02-08From 2021-01-012020-12-3155.19M+0.6%2023-02-09From 2020-01-012019-12-3154.85M+3.4%2022-02-24From 2019-01-012018-12-3153.05M+18.6%2021-02-11From 2018-01-012017-12-3144.74M+3.0%2020-02-26From 2017-01-012016-12-3143.45M+2.8%2019-02-19From 2016-01-012015-12-3142.25M+15.2%2018-02-15From 2015-01-012014-12-3136.69M+20.9%2017-02-17From 2014-01-012013-12-3130.35M+7.5%2016-02-12From 2013-01-012012-12-3128.23M+0.4%2015-03-13From 2012-01-012011-12-3128.11M-1.5%2014-02-25From 2011-01-012010-12-3128.53M+5.6%2013-02-26From 2010-01-012009-12-3127.02M—2012-03-09From 2009-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareEPS (Basic)